Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
33
Active, not recruiting, industry sponsors, Respiratory, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed890
33 trials
Showing 1 to 25, recently updated first.
- Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPDPivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05612035 · 129 participants · Start Mar 16, 2023 · Primary completion Apr 9, 2026
Drug: Frespaciguat; Placebo · For: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
Sites: San Francisco, California; Aurora, Colorado; Sebring, Florida · 85 sites in all
- A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard TreatmentActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07036523 · 81 participants · Start Nov 13, 2025 · Primary completion Mar 11, 2027
Drug: BI 765423; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Gainesville, Florida; Ocala, Florida · 46 sites in all
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial HypertensionActive, not recruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT03492177 · 63 participants · Start Jul 23, 2018 · Primary completion Mar 28, 2022
Drug: selexipag (Uptravi) · For: Pulmonary Arterial Hypertension
Sites: Aurora, Colorado; Iowa City, Iowa; Seattle, Washington · 34 sites in all
- Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)Active, not recruiting
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
NCT05270525 · 70 participants · Start May 27, 2022 · Primary completion Mar 1, 2027
Drug: Ensifentrine; Placebo and 1 more · For: Pulmonary Disease, Chronic Obstructive, COPD
Sites: Birmingham, Alabama; Ann Arbor, Michigan; Pittsburgh, Pennsylvania
- A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.Pivotal-lookingActive, not recruiting
Vicore Pharma ABIndustry
NCT06588686 · 378 participants · Start Dec 9, 2024 · Primary completion May 2027
Drug: Buloxibutid; Placebo · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Birmingham, Alabama; Redding, California; Sacramento, California · 104 sites in all
- A Study to Evaluate Solrikitug in Participants With COPD (ZION)Pivotal-lookingActive, not recruiting
Uniquity One (UNI)Industry
NCT06496620 · 182 participants · Start Aug 14, 2024 · Primary completion Sep 23, 2026
Drug: Biological: Solrikitug low dose; Biological: Solrikitug high dose · For: COPD
Sites: Birmingham, Alabama; Sheffield, Alabama; Peoria, Arizona · 110 sites in all
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06748053 · 307 participants · Start Feb 10, 2025 · Primary completion Jul 14, 2026
Drug: GSK5784283; Placebo · For: Asthma
Sites: Little Rock, Arkansas; Long Beach, California; Los Angeles, California · 137 sites in all
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)Pivotal-lookingActive, not recruiting
Insmed IncorporatedIndustry
NCT05649748 · 91 participants · Start Mar 7, 2023 · Primary completion Dec 31, 2026
Drug: Treprostinil Palmitil; Placebo · For: Pulmonary Arterial Hypertension
Sites: Jacksonville, Florida; Tampa, Florida; Chicago, Illinois · 45 sites in all
- WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingActive, not recruiting
Mediar TherapeuticsIndustry
NCT06967805 · 168 participants · Start May 5, 2025 · Primary completion Aug 2027
Drug: MTX-463 · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Newport Beach, California · 59 sites in all
- Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This MedicinePivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT05846230 · 268 participants · Start Sep 8, 2023 · Primary completion Mar 31, 2027
Drug: BI 1291583; Placebo matching BI 1291583 · For: Bronchiectasis
Sites: Newport Beach, California; Sacramento, California; Gainesville, Florida · 103 sites in all
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06676319 · 556 participants · Start Nov 7, 2024 · Primary completion Jun 21, 2027
Drug: Lunsekimig; Short-Acting Beta Agonists (SABA) and 4 more · For: Asthma
Sites: Saraland, Alabama; Chandler, Arizona; Sun City, Arizona · 221 sites in all
- Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionActive, not recruiting
Cumberland PharmaceuticalsIndustry
NCT02682511 · 34 participants (planned) · Start Jan 2017 · Primary completion Mar 2026
Drug: Oral Ifetroban; Oral Placebo · For: Scleroderma, Diffuse; Scleroderma, Systemic; Scleroderma, Limited and 5 more
Sites: Tucson, Arizona; Los Angeles, California; Weston, Florida · 13 sites in all
- A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CFPivotal-lookingActive, not recruiting
ReCode TherapeuticsIndustry
NCT06237335 · 128 participants · Start Feb 1, 2024 · Primary completion Nov 2026
Drug: RCT2100; RCT2100 and 3 more · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Palo Alto, California · 23 sites in all
- A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDPivotal-lookingActive, not recruiting
Upstream Bio Inc.Industry
NCT06981078 · 666 participants (planned) · Start Jul 2, 2025 · Primary completion Oct 2027
Drug: Verekitug · For: Chronic Obstructive Pulmonary Disease
Sites: Bakersfield, California; Encino, California; Lomita, California · 242 sites in all
- Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPFPivotal-lookingActive, not recruiting
Daewoong Pharmaceutical Co. LTD.Industry
NCT05389215 · 102 participants (planned) · Start Jul 29, 2022 · Primary completion Oct 13, 2026
Drug: DWN12088; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Mesa, Arizona; Phoenix, Arizona; San Francisco, California · 30 sites in all
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaPivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT05851443 · 247 participants · Start Jul 11, 2023 · Primary completion Nov 20, 2026
Drug: povorcitinib; ICS-LABA · For: Moderate to Severe Asthma
Sites: Birmingham, Alabama; Bakersfield, California; Upland, California · 82 sites in all
- A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)Pivotal-lookingActive, not recruiting
Upstream Bio Inc.Industry
NCT06966479 · 396 participants · Start May 21, 2025 · Primary completion Sep 2027
Drug: Verekitug; Placebo · For: Severe Asthma
Sites: Bakersfield, California; Northridge, California; Upland, California · 102 sites in all
- A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisPivotal-lookingActive, not recruiting
Calluna Pharma ASIndustry
NCT06736990 · 150 participants (planned) · Start Jun 20, 2025 · Primary completion Nov 2026
Drug: CAL101; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Los Angeles, California; Denver, Colorado; Miami, Florida · 54 sites in all
- Phase ll Study of HEC585 in Patients With IPFPivotal-lookingActive, not recruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT05060822 · 270 participants (planned) · Start Jun 30, 2021 · Primary completion Jul 16, 2025
Drug: HEC585; Pirfenidone and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Beijing, China
- Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingActive, not recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07108699 · 180 participants (planned) · Start Aug 13, 2025 · Primary completion Aug 30, 2026
Drug: HSK39004 Dry Powder Inhaler-0.75mg; HSK39004 Dry Powder Inhaler-1.5mg and 1 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Chengdu, China
- A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06789289 · 256 participants · Start Mar 17, 2025 · Primary completion Mar 17, 2027
Drug: TQC2938 injection; TQC2938 injection Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Hefei, China; Beijing, China; Chongqing, China · 40 sites in all
- Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)Active, not recruiting
Thirty Respiratory LimitedIndustry
NCT06663176 · 60 participants (planned) · Start Oct 16, 2024 · Primary completion Feb 5, 2028
Drug: RESP302; RESP303 · For: Non-Cystic Fibrosis Bronchiectasis
Sites: Kyiv, Ukraine
- A Phase IIb Study of 610 in Participants With Severe Eosinophilic AsthmaPivotal-lookingActive, not recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT06680947 · 225 participants (planned) · Start Dec 20, 2024 · Primary completion Feb 2027
Drug: 610; 610 and 1 more · For: Asthma
Sites: Shanghai, China
- A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD PatientsActive, not recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07331402 · 12 participants (planned) · Start Jul 28, 2025 · Primary completion Dec 30, 2025
Drug: HSK39004 inhalation suspension · For: COPD Patients
Sites: Shenyang, China
- A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingActive, not recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT06707883 · 258 participants · Start Dec 31, 2024 · Primary completion Dec 2026
Drug: TQC2731 injection; TQC2731 Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Chuzhou, China; Hefei, China; Huainan, China · 60 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.